How to Help Your Patients Save Money on RIMSO-50: A Provider's Guide to Savings Programs

For patients with interstitial cystitis (IC/BPS), RIMSO-50 (dimethyl sulfoxide) is not just a treatment — it is often a quality-of-life lifeline. But at a retail price of $700–$900 per 50 mL dose, the cost of biweekly treatments can quickly become a financial barrier to consistent care. For providers who want to ensure their patients can access and maintain RIMSO-50 therapy, understanding the cost landscape and the tools available to reduce it is essential.

This guide covers RIMSO-50 billing, insurance strategies, discount resources, and patient assistance options from a provider's perspective in 2026.

Understanding How RIMSO-50 Is Billed

RIMSO-50 is not a retail pharmacy medication — it is an in-office procedure drug billed under the medical benefit. The relevant billing code is HCPCS J1212 (dimethyl sulfoxide, 50 mL). This is critical for helping patients understand their cost exposure, because:

The cost falls under the patient's medical deductible and cost-sharing — not their pharmacy deductible

Pharmacy discount cards (GoodRx, SingleCare) may not apply to procedure-billed drug costs

Medicare Part D does not cover RIMSO-50; it may be covered under Part B when administered in an outpatient clinical setting

Practices should train billing staff to consistently use J1212 and to document medical necessity clearly to minimize denials.

Navigating Insurance Coverage for RIMSO-50

Most commercial insurance plans will cover RIMSO-50 when billed correctly and when medical necessity is established. Strategies to maximize insurance coverage:

Pre-authorization: Check whether the patient's plan requires prior authorization for RIMSO-50 (J1212) before the first treatment. Submit documentation including the IC diagnosis code (N30.10 or N30.11), failed or inadequate response to first-line therapies, and clinical rationale.

Appeals for denials: RIMSO-50 is the only FDA-approved intravesical IC therapy. When appealing a denial, this fact — combined with documented IC diagnosis and symptom severity — constitutes strong medical necessity. Provide clinical notes and relevant AUA guideline citations (e.g., AUA IC/BPS Guidelines, 2022 update).

Medicare Part B: For Medicare patients, ensure RIMSO-50 is billed under Part B as an administered drug. ASP pricing from CMS applies. Between 2022 and 2024, AWP and WAC for RIMSO-50 saw price increases, so stay current on CMS reimbursement rates.

Switching to the Generic: The Easiest Cost Reduction

Generic dimethyl sulfoxide 50% intravesical solution (Sandoz) is FDA-approved and bioequivalent to brand RIMSO-50. Sourcing and using the generic is often the single most effective cost reduction available to practices. Because generic and brand-name drugs may flow through different distributors, the generic may also be more consistently available and competitively priced. Practices should proactively compare acquisition costs and use the generic when cost savings are significant.

When the Drug Is Dispensed Through a Pharmacy: Discount Cards

In scenarios where RIMSO-50 is dispensed directly to a patient through a specialty pharmacy (rather than billed as a procedure), pharmacy discount cards can reduce costs. Direct patients to:

GoodRx: Reduces RIMSO-50 to approximately $742 per dose (about 15% below retail)

SingleCare: Reduces RIMSO-50 to approximately $715 per dose

Remind patients that discount cards cannot be combined with insurance. They should compare their insurance cost-sharing with the discount card price and use whichever is lower.

Patient Assistance and Charitable Programs

For patients who are uninsured or significantly underinsured, the following resources may help:

NeedyMeds.org: Comprehensive database of patient assistance programs, disease funds, and discount resources. Search for "dimethyl sulfoxide" to find current options.

RxAssist.org: Searchable database of pharmaceutical company PAPs. Check for any Mylan (Viatris) programs for RIMSO-50.

Manufacturer contact: Contact Mylan/Viatris directly at 866-316-7263 to inquire about patient assistance program availability for RIMSO-50.

Interstitial Cystitis Association: The ICA may be aware of disease-specific financial assistance programs for IC patients.

Incorporating Cost Conversations Into Your Practice

Research consistently shows that financial barriers lead patients to skip or delay treatments. In IC, this has a direct impact on symptom control and quality of life. Consider incorporating these best practices into your patient care workflow:

Before starting RIMSO-50, have a brief cost and coverage conversation with every patient. Confirm their insurance type and whether RIMSO-50 is covered under their medical benefit.

Assign a staff member to handle prior authorization proactively so it doesn't delay the first treatment.

Create a patient handout with cost-saving resources (NeedyMeds, GoodRx for pharmacy scenarios, medfinder for location assistance) that staff can distribute during scheduling.

For patients experiencing financial hardship, proactively offer the generic as a cost-saving measure without waiting for the patient to ask.

How medfinder Supports Your Patients' Access

When RIMSO-50 is difficult to find or a patient is coordinating across multiple pharmacies to find the best price, medfinder reduces the burden on patients by calling pharmacies on their behalf. This is particularly useful for patients who are balancing IC-related fatigue or disability with the added stressor of medication access challenges. Consider including medfinder as a resource in your patient education materials.

For patient-facing information on saving money, direct them to: How to Save Money on RIMSO-50 in 2026: Coupons, Discounts, and Patient Assistance.